November 2022 in “Journal of the Endocrine Society” Long-term treatment with buprenorphine/naloxone for opioid addiction may lead to secondary adrenal insufficiency.
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
January 2023 in “Mastology” Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.
42 citations
,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
2 citations
,
January 2012 HSA nanoparticles can improve tamoxifen delivery for breast cancer treatment, reducing side effects.
52 citations
,
May 1993 in “Southern Medical Journal” Imuvert can prevent some chemotherapy-induced hair loss.
19 citations
,
June 1997 in “The Journal of Clinical Endocrinology & Metabolism” The treatment successfully lowered testosterone levels and reduced symptoms.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
4 citations
,
February 2023 in “Frontiers in Oncology” Nano-Pulse Stimulation™ Therapy is more effective and less damaging than cryoablation for treating melanoma tumors in mice.
2 citations
,
July 2017 in “Oman medical journal” A man with a rare adrenal cancer showed unusual symptoms and died four months after diagnosis.
July 2019 in “Journal of the ASEAN Federation of Endocrine Societies” The woman had a rare adrenal tumor removed, and she recovered well with no signs of the tumor returning.
12 citations
,
June 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
59 citations
,
May 1995 in “Journal of the American Academy of Dermatology” September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
9 citations
,
May 2024 in “Journal of Clinical & Translational Endocrinology” Gender affirming hormone therapy improves outcomes in gender affirmation surgery.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
June 2023 in “Revista de Ciências Médicas e Biológicas” Proper management of skin and hair side effects from chemotherapy improves patients' quality of life.
Combining regenerative therapy with light treatment can effectively promote hair growth.
October 2025 in “Annals of Medicine and Surgery” Retinoids may improve hair growth in androgenic alopecia when used with other treatments.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
3 citations
,
October 2003 in “Annals of Oncology” A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.
3 citations
,
May 2011 in “Journal of Obstetrics and Gynaecology” A woman's pelvic pain and bleeding led to finding and successfully treating a rare benign tumor in her reproductive system.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
February 2017 in “대한피부과학회지” Combining low-dose dutasteride with finasteride improved a man's hair loss.